Send Comments to IFOND

International Foundation for Optic Nerve Disease
P. O. Box 777, Cornwall NY 12518, USA

 
If you find this site helpful or IFOND sponsored research worthwhile, please donate to IFOND at the address above, or JustGive.org.

Ischaemic Optic Nerve Disease

IFOND NEWS

Fundraising

IFOND gratefully acknowledges all our generous donors. For years a large portion of our funding has been from the IFOND annual golf outing. This happy event will continue. Email us if you are attending. Recently we have also been getting a steady but modest flow of online donations from many sources. McCORMICK& COMPANY, INC. have been generous regular donors with their Matching Gifts Program. In July 2010 we were graced with a large donation from The Welcoming Club of Garden City. See our fundraising section for further details and recognition. Without your generous giving our important research would not happen.

Alfredo A. Sadun, MD, PhD, wins 2012 William F. Hoyt Award

The IFOND Board is very proud to have Professor Aldredo Sadun as a scientific advisor. This November our most distinguished and effective teacher, clinician and researcher was awarded by the American Academy of Ophthalomology and the North American Neuro-Ophthalmology Society their highest honour in Neuro-Ophthalmology, The William F. Hoyt Lecturer Award.

17th Annual Golf Outing success

Don Diehl, Golf Outing Chair, reports that the 17th Annual Golf Outing Fundraising Event held on September,10 2012 was a resounding success with over 125 golfers participating and many other generous sponsors and donors contributing to the effort.

Idebenone treatment for LHON

A randomized placebo controlled study published in the journal Brain showed idebenone to be an effective treatment for LHON. Idebenone is a synthetic benzoquinone, co-enzyme Q10 like substance, potent antioxidant and inhibitor of lipid peroxidation, which also interacts with the mitochondrial electron transport chain and facilitates mitochondrial electron flux through by-passing complex I. It was shown in the study to be well tolerated and have modest effectiveness in about half of LHON patients treated. The result confirms retrospective treatment data soon to be published. People treated early in onset and for prolonged periods were likely to benefit most.

LHON treatment trials

IFOND scientific members are involved in new LHON treatment trials using the Vitamin E metabolite substance, Alpha-tocotrienol-quinone, coded EPI-743, a potent antioxidant. Find Dr Jerry Sherman's presentation of his optometric case findings in this promising open label study in Review of Optometry Case 38 Leber's Hereditary Optic Neuropathy [Note: be patient for the 60 second wait to download the 100 slides.]

Brazil LHON Field Trip Reports

With your support, IFOND sponsors research on the world's largest Leber Hereditary Optic Neuropathy [LHON] pedigree. In our projects section Dr Alfredo Sadun, the study co-ordinator, has summarized the studies to date since 2001 when they began with IFOND sponsorship. We have pushed the frontiers of knowledge about Leber Hereditary Optic Neuropathy. Please donate to IFOND to see this and other worthwhile IFOND work continue.

In Ischemic Optic Neuropathy (ION) visual loss occurs when the optic nerve fails to receive a continuous, sufficient blood supply. The most common risk factors associated with ION are older age, diabetes, hypertension, and arteriosclerosis.

ION is the most common cause of visual loss in persons over 50 years of age, affecting millions of persons in the United States. Ophthalmologists are therefore quite familiar with the clinical picture of a patient with reduced blood supply (ischemia) to the optic nerve. Urgent treatment is necessary to save vision if the cause is inflammatory blockage of arteries, but no treatment is yet available for the non inflammatory type.

Current studies, however, offer the hope of future drug treatment. Recently researchers have begun to study what happens between the loss of blood flow (perfusion) into the optic nerve, and the onset of irreversible visual loss. It is now known that a complex sequence of chemical events leading to a loss of oxygen and glucose in cells of the optic nerve ultimately results in a toxic overload of calcium (Ca) which leads to the destruction of optic nerve axons and the resultant visual loss. The chemical complexity of this process means that there is not just one, but a number of steps along the way before ischemia sets in, where different drugs might be able to prevent the ultimate destruction of optic nerve cells. Several laboratories are already working on therapeutic methods aimed at preventing visual loss in ION.


See Also

Wikipedia: Anterior ischemic optic neuropathy


If you find this site helpful or IFOND sponsored research worthwhile, please donate to IFOND at the address below, or JustGive.org.

The International Foundation for Optic Nerve Disease
P. O. Box 777, Cornwall NY 12518, USA.
TEL/FAX (845) 534 7250
Email: ifond@aol.com
Web site: http://www.ifond.org/


IFOND is registered service mark of The International Foundation for Optic Nerve Disease

Copyright 1999-2013, International Foundation for Optic Nerve Disease.


The information contained on this website should not be considered medical guidance or professional advice. IFOND is not responsible for errors or omissions in information provided on this site or actions resulting from its use. IFOND does not publish all information from all available sources on optic nerve disease. IFOND is not responsible for the validity of the studies or reviews nor is it an advocate of studies or reviews mentioned on or linked from the IFOND web site. IFOND does not endorse or recommend participation in any particular clinical trial or treatment protocol which may be mentioned on this site. Direct any questions concerning your personal health to your appropriate health care professional.